File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Research progress of stem cells in the treatment of retinal degenerative diseases

TitleResearch progress of stem cells in the treatment of retinal degenerative diseases
Authors
KeywordsAge-related macular degeneration
Cell transplantation therapy
Induced pluripotent stem cells
Photoreceptor
Retinal pigment epithelium
Retinitis pigmentosa
Issue Date2018
Citation
Chinese Journal of Experimental Ophthalmology, 2018, v. 36, n. 11, p. 871-877 How to Cite?
AbstractEyes are important human organs, and retinal degenerative diseases can cause irreversible blindness.Up to date, cell transplantation is an important method for the treatment of degenerative eye diseases.Because the number of adult eye stem cells is rather limited, it is still very difficult to activate endogenous adult stem cells as a way to treat degenerative eye diseases.Therefore, photoreceptor cells (photoreceptor) and retinal pigment epithelium (RPE) cells generated from pluripotent stem cells include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be an effective source of cells for transplantation.This article described the major types of retinal degenerative diseases including retinitis pigmentosa (RP) and age-related macular degeneration (AMD) by focusing on their pathological process and development of stem cell transplantation.We reviewed the related stem cell therapies and research status of two different vulnerable cells, RPE and photoreceptor cell in degenerative ophthalmopathy.We also discussed the value and limitations of cell transplantation therapy and the prospect of future treatment.
Persistent Identifierhttp://hdl.handle.net/10722/365598
ISSN
2023 SCImago Journal Rankings: 0.140

 

DC FieldValueLanguage
dc.contributor.authorZhang, Kefan-
dc.contributor.authorQu, Xiuxia-
dc.contributor.authorFan, Guoping-
dc.date.accessioned2025-11-05T09:46:20Z-
dc.date.available2025-11-05T09:46:20Z-
dc.date.issued2018-
dc.identifier.citationChinese Journal of Experimental Ophthalmology, 2018, v. 36, n. 11, p. 871-877-
dc.identifier.issn2095-0160-
dc.identifier.urihttp://hdl.handle.net/10722/365598-
dc.description.abstractEyes are important human organs, and retinal degenerative diseases can cause irreversible blindness.Up to date, cell transplantation is an important method for the treatment of degenerative eye diseases.Because the number of adult eye stem cells is rather limited, it is still very difficult to activate endogenous adult stem cells as a way to treat degenerative eye diseases.Therefore, photoreceptor cells (photoreceptor) and retinal pigment epithelium (RPE) cells generated from pluripotent stem cells include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be an effective source of cells for transplantation.This article described the major types of retinal degenerative diseases including retinitis pigmentosa (RP) and age-related macular degeneration (AMD) by focusing on their pathological process and development of stem cell transplantation.We reviewed the related stem cell therapies and research status of two different vulnerable cells, RPE and photoreceptor cell in degenerative ophthalmopathy.We also discussed the value and limitations of cell transplantation therapy and the prospect of future treatment.-
dc.languageeng-
dc.relation.ispartofChinese Journal of Experimental Ophthalmology-
dc.subjectAge-related macular degeneration-
dc.subjectCell transplantation therapy-
dc.subjectInduced pluripotent stem cells-
dc.subjectPhotoreceptor-
dc.subjectRetinal pigment epithelium-
dc.subjectRetinitis pigmentosa-
dc.titleResearch progress of stem cells in the treatment of retinal degenerative diseases-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3760/cma.j.issn.2095-0160.2018.11.011-
dc.identifier.scopuseid_2-s2.0-85063301448-
dc.identifier.volume36-
dc.identifier.issue11-
dc.identifier.spage871-
dc.identifier.epage877-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats